Guillain-Barrè syndrome (GBS) refers to a group of immune-mediated, rapidly progressive polyneuropathies. Before the clinical onset, most patients present with potentially triggering events in their history, including infections and vaccinations. The commonly accepted pathogenic mechanism is an autoimmune response targeting the axons and myelin of peripheral nerves. Diagnosis is based on clinical criteria, though it may be supported by consistent laboratory, neurophysiological and neuroradiological findings, increasing diagnostic reliability. Due to its sudden and invalidating onset, GBS represents a possible cause of access to the emergency room. Therefore, physicians must take into account GBS clinical heterogeneity to promote an early diagnosis and promptly start acute phase treatment and supportive therapies. © 2022, Biolife s.a.s.. All rights reserved.
Overview of Guillain-Barrè Syndrome
Amore G;Spoto G;Valentini G;Germanò E;Colavita L;Gitto E;Di Rosa G;Nicotera AG
2022-01-01
Abstract
Guillain-Barrè syndrome (GBS) refers to a group of immune-mediated, rapidly progressive polyneuropathies. Before the clinical onset, most patients present with potentially triggering events in their history, including infections and vaccinations. The commonly accepted pathogenic mechanism is an autoimmune response targeting the axons and myelin of peripheral nerves. Diagnosis is based on clinical criteria, though it may be supported by consistent laboratory, neurophysiological and neuroradiological findings, increasing diagnostic reliability. Due to its sudden and invalidating onset, GBS represents a possible cause of access to the emergency room. Therefore, physicians must take into account GBS clinical heterogeneity to promote an early diagnosis and promptly start acute phase treatment and supportive therapies. © 2022, Biolife s.a.s.. All rights reserved.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
